• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Ntrk Fusion Gene Positive Advanced Solid Tumor Market

    ID: MRFR/LS/25961-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Research Report By Treatment Type (Targeted Therapy, Chemotherapy, Immunotherapy, Surgery, Radiation Therapy), By Tumor Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Pancreatic Cancer, Sarcoma), By Market Stage (Early Stage, Advanced Stage, Metastatic Stage), By Biomarker Status (NTRK1 Gene Fusion Positive, NTRK2 Gene Fusion Positive, NTRK3 Gene Fusion Positive) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Ntrk Fusion Gene Positive Advanced Solid Tumor Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Ntrk Fusion Gene Positive Advanced Solid Tumor Market Summary

    The Global NTRK Fusion Gene Positive Advanced Solid Tumor Market is poised for substantial growth, projected to reach 83.61 USD Billion by 2035.

    Key Market Trends & Highlights

    NTRK Fusion Gene Positive Advanced Solid Tumor Key Trends and Highlights

    • The market is valued at 13.5 USD Billion in 2024 and is expected to grow to 83.6 USD Billion by 2035.
    • The compound annual growth rate (CAGR) for the market is estimated at 18.02% from 2025 to 2035.
    • This market expansion indicates a robust demand for targeted therapies in oncology.
    • Growing adoption of precision medicine due to increased awareness of genetic testing is a major market driver.

    Market Size & Forecast

    2024 Market Size 13.51 (USD Billion)
    2035 Market Size 83.61 (USD Billion)
    CAGR (2025-2035) 18.02%

    Major Players

    Bayer AG, Roche, Array BioPharma, Merck KGaA, Biogen, Agenus, Exelixis, Ignyta, Genentech, Blueprint Medicines, Novartis, Loxo Oncology, Tiziana Life Sciences, AbbVie, Daiichi Sankyo, Epizyme

    Ntrk Fusion Gene Positive Advanced Solid Tumor Market Trends

    Market drivers for the NTRK fusion gene positive advanced solid tumor market include the growing incidence of advanced solid tumors with NTRK rearrangements, innovation in the field of precision medicine, and increasing adoption of companion diagnostics. The active development and use of combined therapy, patient selection with a focus on biomarkers, and the creation of potent and selective next-wave TRK inhibitors reflect the great potential opportunities.

    Recent developments include the growing awareness of NTRK fusions in a wider variety of tumor types and new models for NTRK liquid biopsy assays, as well as the increasing interest of academia, industry, and regulators working together in drug development.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    The increasing recognition of NTRK fusion genes as actionable targets in advanced solid tumors is reshaping therapeutic strategies and fostering innovation in precision oncology.

    National Cancer Institute

    Ntrk Fusion Gene Positive Advanced Solid Tumor Market Drivers

    Rising Incidence of NTRK Fusion Positive Tumors

    The Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Industry is experiencing growth driven by the increasing incidence of NTRK fusion positive tumors. These tumors, which can occur in various solid cancers, are becoming more frequently diagnosed due to advancements in genetic testing and awareness among healthcare professionals. As of 2024, the market is valued at approximately 13.5 USD Billion, reflecting the urgent need for targeted therapies. The rising number of patients diagnosed with these tumors necessitates innovative treatment options, thereby propelling market expansion. This trend is likely to continue as more patients are identified, contributing to the overall growth of the industry.

    Market Segment Insights

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Treatment Type Insights

    The NTRK Fusion Gene Positive Advanced Solid Tumor Market is segmented by treatment type, and Targeted Therapy is expected to dominate the segment. The growth of this segment will be attributed to the increasing adoption of precision medicine and the development of novel targeted therapies. The Chemotherapy segment is also expected to grow significantly due to the rising use of combination therapies and the development of new chemotherapy agents. The Immunotherapy segment is expected to demonstrate steady growth as there become more understanding of the immune system’s role in cancer and the development of novel immunotherapeutic agents.

    The Chemotherapy segment is expected to demonstrate a CAGR of 16.0% and reach USD 16.8 billion by 2024. The market share of the Immunotherapy segment is projected to reach USD 10.2 billion by 2024 with a CAGR of 14.0%. The growth of the Surgery and Radiation Therapy segments is believed to reach 12.0% and 10.0%, respectively, during the forecast period.

    The increasing incidence of cancer and the growing awareness of NTRK fusion genes are expected to be the key growth factors for the NTRK Fusion Gene Positive Advanced Solid Tumor Market.Other drivers include the development of novel therapies and the rising adoption of precision medicine. The market is also anticipated to benefit from the increasing government funding for cancer researches and the growing number of clinical trials.

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Tumor Type Insights

    The NTRK Fusion Gene Positive Advanced Solid Tumor Market is segmented into Tumor Type, which include Lung Cancer, Colorectal Cancer, Breast Cancer, Pancreatic Cancer, and Sarcoma. Lung Cancer accounted for the largest share of the market in 2023, and is expected to continue to dominate the market throughout the forecast period. The high prevalence of lung cancer, along with the increasing adoption of NTRK-targeted therapies, is driving the growth of this segment.

    Colorectal Cancer is the second largest segment, and is expected to grow at a significant rate during the forecast period.The rising incidence of colorectal cancer, coupled with the availability of effective NTRK inhibitors, is contributing to the growth of this segment. Breast Cancer is another major segment, and is expected to witness steady growth over the forecast period. The increasing awareness about NTRK fusions in breast cancer, along with the development of novel therapies, is fueling the growth of this segment.

    Pancreatic Cancer and Sarcoma are smaller segments, but are expected to grow at a moderate pace during the forecast period. The unmet medical need for effective treatments in these cancers, along with the potential of NTRK inhibitors, is driving the growth of these segments.

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Market Stage Insights

    The NTRK Fusion Gene Positive Advanced Solid Tumor Market is segmented by Market Stage into Early Stage, Advanced Stage, and Metastatic Stage. Among these segments, the Advanced Stage segment held the largest market share of over 50% in 2023 and is expected to continue dominating the market during the forecast period The high prevalence of NTRK fusion-positive tumors in advanced stages of cancer, coupled with the availability of targeted therapies, is driving the growth of this segment.

    Furthermore, the increasing adoption of next-generation sequencing (NGS) techniques for tumor profiling is aiding in the early detection and diagnosis of NTRK fusion-positive tumors, leading to the initiation of appropriate treatment at an advanced stage.

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Biomarker Status Insights

    Biomarker Status Segment Insights and Overview The NTRK Fusion Gene Positive Advanced Solid Tumor Market is segmented by Biomarker Status into NTRK1 Gene Fusion Positive, NTRK2 Gene Fusion Positive, and NTRK3 Gene Fusion Positive. Among these segments, NTRK1 Gene Fusion Positive is anticipated to hold the largest market share in 2023. The market growth of this segment is primarily attributed to the increasing prevalence of NTRK1 gene fusions in various advanced solid tumors, such as lung cancer, colorectal cancer, and sarcoma.

    The NTRK2 Gene Fusion Positive segment is estimated to witness substantial growth over the forecast period due to the rising awareness and adoption of targeted therapies that specifically inhibit NTRK2 fusions. Moreover, the increasing number of clinical trials evaluating the efficacy and safety of NTRK2 inhibitors is expected to drive segment growth. The NTRK3 Gene Fusion Positive segment is projected to have a moderate market share compared to other segments. However, the segment is expected to experience steady growth as research efforts continue to explore the role of NTRK3 fusions in cancer development and identify effective treatment strategies.

    Get more detailed insights about Ntrk Fusion Gene Positive Advanced Solid Tumor Market Research Report-Forecast till 2034
    Request Free Sample

    Regional Insights

    The regional landscape of the NTRK Fusion Gene Positive Advanced Solid Tumor Market showcases significant variations in market dynamics. North America and Europe collectively accounted for over 60% of the market revenue in 2023. The dominance of these regions can be attributed to factors such as high healthcare expenditure, advanced healthcare infrastructure, and a large patient population with access to advanced diagnostic techniques.

    APAC is anticipated to witness substantial growth over the forecast period, owing to increasing healthcare spending, rising awareness about cancer, and growing investments in research and development.South America and MEA are expected to exhibit moderate growth, driven by improving healthcare systems and government initiatives aimed at improving access to cancer care.

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    Leading NTRK Fusion Gene Positive Advanced Solid Tumor Market industry players are focusing on gaining a competitive edge by spending on research and development, forming strategic alliances, and expanding product portfolios. Leading NTRK Fusion Gene Positive Advanced Solid Tumor Market players are emphasizing the development of advanced and innovative therapies that can help improve patient outcomes and address unmet medical needs. The NTRK Fusion Gene Positive Advanced Solid Tumor Market is highly competitive, with key industry players leading the market and holding a major portion of the market share.

    Leading players are continuously concentrating on NTRK Fusion Gene Positive Advanced Solid Tumor Market development and innovations. The competitive landscape is anticipated to remain fragmented with the entry of new players in the coming years. Bayer AGBayer AG operates as a leading company in the NTRK Fusion Gene Positive Advanced Solid Tumor Market. Bayer AG provides a range of products for NTRK Fusion Gene Positive Advanced Solid Tumor, such as Vitrakvi and Bay 27796.

    Bayer AG is headquartered in a strong global presence and has a strong focus on providing innovative therapies to patients suffering from NTRK Fusion Gene Positive Advanced Solid Tumor. The company has a strong product pipeline in different stages of the product life cycle. The development of new products and a strong pipeline are primary factors helping drive the company’s growth in the NTRK Fusion Gene Positive Advanced Solid Tumor Market.RocheRoche International AG is a leading Swiss multinational healthcare company that manufactures, develops, and markets a wide range of pharmaceuticals and diagnostics.

    The company’s pharmaceuticals business comprises oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In terms of revenue, Roche is a market-leading player in the NTRK Fusion Gene Positive Advanced Solid Tumor Market. The company’s major products, Rozlytrek and Gavreto, are used for NTRK Fusion Gene Positive Advanced Solid Tumor applications. The company has a strong focus on the development of advanced and innovative therapies for improving patient outcomes.

    Key Companies in the Ntrk Fusion Gene Positive Advanced Solid Tumor Market market include

    Industry Developments

    The NTRK fusion gene positive advanced solid tumor market is poised to experience significant growth over the coming years. Recent advancements in targeted therapies have revolutionized the treatment landscape for patients with this rare and aggressive form of cancer. The development of TRK inhibitors, such as larotrectinib and entrectinib, has shown promising results in clinical trials, leading to improved outcomes and reduced side effects. The market is expected to witness a surge in demand for these therapies as more patients are diagnosed with NTRK fusion-positive tumors.

    Key players in the market are actively involved in research and development to expand the treatment options and improve patient care. Strategic collaborations and partnerships are also prevalent in the industry, with companies seeking to combine their expertise and resources to accelerate the development of innovative therapies.

    Future Outlook

    Ntrk Fusion Gene Positive Advanced Solid Tumor Market Future Outlook

    The NTRK Fusion Gene Positive Advanced Solid Tumor Market is projected to grow at an 18.02% CAGR from 2025 to 2035, driven by advancements in targeted therapies and increasing diagnostic capabilities.

    New opportunities lie in:

    • Develop innovative combination therapies to enhance treatment efficacy and patient outcomes. Invest in next-generation sequencing technologies for improved detection of NTRK fusions. Expand global access to targeted therapies through strategic partnerships and collaborations.

    By 2035, the market is expected to reach a robust position, reflecting substantial growth and innovation.

    Market Segmentation

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Tumor Type Outlook

    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Pancreatic Cancer
    • Sarcoma

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Market Stage Outlook

    • Early Stage
    • Advanced Stage
    • Metastatic Stage

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Treatment Type Outlook

    • Targeted Therapy
    • Chemotherapy
    • Immunotherapy
    • Surgery
    • Radiation Therapy

    NTRK Fusion Gene Positive Advanced Solid Tumor Market Biomarker Status Outlook

    • NTRK1 Gene Fusion Positive
    • NTRK2 Gene Fusion Positive
    • NTRK3 Gene Fusion Positive

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024   13.51 (USD Billion)
    Market Size 2025   15.95 (USD Billion)
    Market Size 2035 83.61 (USD Billion)
    Compound Annual Growth Rate (CAGR) 18.02% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2020 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled Array BioPharma, Merck KGaA, Biogen, Agenus, Exelixis, Bayer, Ignyta, Genentech, Blueprint Medicines, Novartis, Loxo Oncology, Tiziana Life Sciences, AbbVie, Daiichi Sankyo, Epizyme
    Segments Covered Treatment Type, Tumor Type, Market Stage, Biomarker Status, Regional
    Key Market Opportunities Precision medicine Expanded patient eligibility Emerging targeted therapies Access to healthcare Growing awareness
    Key Market Dynamics Increasing prevalence of cancer Rising demand for targeted therapies Growing adoption of companion diagnostics Technological advancements and Patent expirations of key drugs
    Countries Covered North America, Europe, APAC, South America, MEA

    FAQs

    What is the market size of the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    The NTRK Fusion Gene Positive Advanced Solid Tumor Market is expected to reach USD 13.51 billion in 2024 and USD 70.84 billion by 2034, exhibiting a CAGR of 18.0% during the forecast period.

    Which region is expected to dominate the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    North America is expected to dominate the market, accounting for the largest revenue share in 2023. However, the Asia-Pacific region is projected to witness the fastest growth over the forecast period.

    What are the key growth drivers of the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    Rising prevalence of cancer, increasing awareness of NTRK fusion-positive tumors, and advancements in targeted therapies are the key growth drivers of the market.

    What are the major applications of NTRK Fusion Gene Positive Advanced Solid Tumors?

    NTRK Fusion Gene Positive Advanced Solid Tumors are primarily used in the treatment of various types of cancer, including lung cancer, colorectal cancer, and sarcoma.

    Who are the key competitors in the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    Key competitors in the market include Bayer AG, Blueprint Medicines Corporation, Eli Lilly and Company, Loxo Oncology (Eli Lilly and Company), and Roche Holding AG.

    What are the challenges faced by the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    High cost of treatment and limited access to NTRK fusion testing are some of the challenges faced by the market.

    What is the impact of the COVID-19 pandemic on the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    The COVID-19 pandemic had a moderate impact on the market due to disruptions in clinical trials and supply chains. However, the market is expected to recover post-pandemic.

    What are the emerging trends in the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    Precision medicine, personalized therapies, and combination therapies are emerging trends in the market.

    What is the future outlook of the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    The market is expected to witness significant growth over the forecast period due to the increasing prevalence of cancer, advancements in targeted therapies, and rising awareness of NTRK fusion-positive tumors.

    What are the key opportunities for growth in the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

    Expansion into emerging markets, development of novel therapies, and collaborations between industry players and research institutions are key opportunities for growth in the market.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Stories
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027